In the NEW era of universal adult hepatitis B vaccination1,*
Protecting your adult Patients Can Be As
HEPLISAV-B is the first and only adult hepatitis B vaccine that provides series completion with just 2 DOSES IN 1 MONTH1-3
See the CDC recommendationTHE ERA OF UNIVERSAL Adult HEPATITIS B VACCINATION IS HERE1
Efficient series completion is more critical than ever1,4
In 2022, the CDC issued a universal recommendation that all adults aged 19-59 receive hepatitis B vaccination.1 Unfortunately, series completion can be an issue with 3-dose options.4
Find out how many more patients are eligible for hepatitis B vaccination in 2022.
Discover how 2-dose HEPLISAV-B can make series completion easier and protect patients faster.2,6
THE TIME FOR A DIFFERENT APPROACH IS NOW AND IT STARTS WITH YOU
Give your healthcare system the benefits of 2-dose HEPLISAV-B2,4,6-8
The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.1
Request more information
Get infoINDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
References: 1. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed April 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 2. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 3. Haber P, Schillie S. Hepatitis B. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:143-164. 4. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 5. Freedman M, Kroger A, Hunter P, Ault KA. Recommended adult immunization schedule, United States, 2020. Ann Intern Med. 2020;172(5):337-347. doi:10.7326/M20-0046 6. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018. 7. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577 8. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.
INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.